Login to Your Account



Amylin, Lilly Enter Supply Deal for Diabetes Drug Exenatide

By Catherine Hollingsworth


Thursday, October 23, 2008
Despite a modest decrease in Byetta (exenatide) sales, Amylin Pharmaceuticals Inc. said it ended that quarter with strong revenues overall and soon will get a $125 million boost from a deal to supply partner Eli Lilly and Co. with a once-weekly version of the drug, upon approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription